TWO YEARS OF DATA FROM THE JEWELFISH STUDY WERE PRESENTED BY ROCHE.

Run for Goodness
HOMEPAGE
WHO ARE WE?
WHAT ARE WE DOING?
HOW CAN YOU SUPPORT?
SMA
CONTACT

DONATION

Homepage

RECENT DEVELOPMENTS

TWO YEARS OF DATA FROM THE JEWELFISH STUDY WERE PRESENTED BY ROCHE.

RECENT DEVELOPMENTS

TWO YEARS OF DATA FROM THE JEWELFISH STUDY WERE PRESENTED BY ROCHE.

ASSOCIATION LAUNCH AND PHOTO EXHIBITION

TITCK MEETINGS

HOPEFUL DAYS ARE COMING FOR SMA PATIENT ÇAĞAN MERİÇ

SMA PATIENTS ARE TREATED AT ESOGÜ

NOTICE ON RELATING AN ALTERATION IN THE RESCRIPT OF HEALTH IMPLEMENTATION SOCIAL SECURITY INSTITUTION

YOU ARE INVITED TO OUR SMA AWARENESS EXHIBITION IN ESPARK

PAINTING CONTEST THEMED "LIVING WITH SMA DISEASE"

18.10.2022

Number of Reads : 5519

Two-year data from the JEWELFISH study, a safety study evaluating Evrysdi in people previously treated with approved or investigational SMA therapies, including Nusinersen (Spinraza) or Onasemnogen Abeparvovec (Zolgensma), published by Roche presented.